Clinical trials: Oral Anticoagulants
Hemophilia A, Hemophilia B
Vitamin K Antagonist Versus Direct Oral Anticoagulant Treatments in Hemophilia
Hemophilia is a rare X-linked bleeding disorder responsible for deficiency of coagulation factor VIII (FVIII) or IX (FIX). The main clinical manifestation is increased bleeding throughout the life which is directly correlated to…
- Conditions
- Hemophilia A, Hemophilia B, Anticoagulant-induced Bleeding
- Trial name
- KADOAH (NCT05804734)
- Testing
- Vitamin K Antagonist - Drug
- Where
- 6 sites in France
- Volunteers
- 54 people
- Sponsor
- Groupe Maladies hémorragiques de Bretagne
Gastrointestinal Bleeding, Antiplatelet Agents
How Often Does the Fecal Test for Occult Blood Turn Positive After Using Blood Thinners?
Blood thinner medications used for cardiovascular disease can cause gastrointestinal bleeding. Early detection of invisible bleeding by performing occult fecal blood test (called fecal immunochemical test, or FIT) can uncover…
- Conditions
- Gastrointestinal Bleeding, Antiplatelet Agents, Oral Anticoagulant Therapy
- Trial name
- NCT07327853
- Testing
- Fecal Immunochemical Test (FIT)
- Where
- Jordan
- Volunteers
- 200 people
- Sponsor
- Jordan Collaborating Cardiology Group
Atrial Fibrillation
Impact of the Information Follow-up Given to Patients on Their Disease Understanding and Therapeutic Adherence in Patients Under Direct Oral Anticoagulants and With Atrial Fibrillation in a Cardiology Department
The primary objective of this study is to measure in patients addressed for Atrial Fibrillation (AF) in the Cardiology-Electrophysiology and Cardiac Stimulation Department of Bordeaux hospital, the impact of a specialized nurse…
- Trial name
- RYTHM-UP AOD (NCT03645564)
- Testing
- Specialized nurse consultation
- Where
- France
- Volunteers
- 221 people
- Sponsor
- University Hospital, Bordeaux
Atrial Fibrillation
A Study to Learn About the Effects of Medicines That Help in Thinning the Blood in People With Atrial Fibrillation (AF) Between 2016 and 2020 in France
The purpose of this study is to look at how many patients with AF had strokes, major bleeding and death in both people who had and had not taken any oral anticoagulant.
- Trial name
- SIFNOS (NCT05838664)
- Testing
- No OAC, VKA, apixaban
- Where
- France
- Volunteers
- 2,140,403 people
- Sponsor
- Pfizer
Craniocerebral Trauma, Cerebral Hemorrhage
Mild Head Injury, Antiplatelets, and Anticoagulants
Approximately 20% of patients with mild head injury presenting to the Emergency Department (ED) is taking antiplatelet agents and 10% is taking oral anticoagulants.
- Trial name
- NCT04741334
- Testing
- direct anticoagulant, antiplatelet drugs, Dicumarols
- Where
- Italy
- Volunteers
- 2,127 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Non Valvular Atrial Fibrillation
Apixaban Versus Rivaroxaban in Non Valvular Atrial Fibrillation
The investigators will first measure the maximum concentration (after 2 hours of intake) and the residual concentration (just before the next intake) after at least 15 consecutive days of treatment.
- Trial name
- APIXA-Xa (NCT06862726)
- Testing
- Anti Xa dosage, Dosage of PT-INR
- Where
- Tunisia
- Volunteers
- 120 people
- Sponsor
- Les Laboratoires des Médicaments Stériles
Novel Oral Anticoagulants, NOACs
Impact of Biomarkers on Pharmacokinetics and Pharmacodynamics of Direct Oral Anticoagulants
It is general that there are many factors for individual differences of drugs in clinical application, of which genetic factors accounted for more than 20%.
- Conditions
- Novel Oral Anticoagulants, NOACs, Rivaroxaban, Apixaban
- Trial name
- NCT03161496
- Testing
- detection of genotype
- Where
- 17 sites in China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Cui Yimin
Gastrointestinal Hemorrhage, Diabetes Complications
Therapeutic Conflicts and Multimorbidity
Clinical practice guidelines do not take into account multimorbidity and various potential therapeutic conflicts. Identifying and quantifying therapeutic conflicts is crucial in multimorbid patients having more than two acute or…
- Conditions
- Gastrointestinal Hemorrhage, Diabetes Complications, Multimorbidity
- Trial name
- NCT02928939
- Testing
- drug-drug or drug-disease interaction
- Where
- Switzerland
- Volunteers
- 1,101 people
- Sponsor
- University of Zurich
Atrial Fibrillation, Stroke
Intention to Prescribe/Take OAC Depending on the Number of Risk Diagrams , and Period for the Estimation of the Risk.
Randomized study concerning the effect of the number of risk diagrams (with treatment +/- without treatment), the period of stroke risk estimation (one year or five years) and the target of prescription (the patient with atrial…
- Trial name
- NCT02746107
- Testing
- decision aid
- Where
- Romania
- Volunteers
- 968 people
- Sponsor
- Cristian Baicus
Atrial Fibrillation
COhort of antithrOmbotic Use and cLinical Outcomes in Patients With Atrial Fibrillation (COOL-AF) Phase 2
Atrial fibrillation (AF) is a leading cause of cardiovascular mortality and morbidity. Asian patients with AF have a higher rate of major bleeding including intracranial hemorrhage (ICH) compared to non-Asians.
- Trial name
- NCT06396299
- Testing
- No intervention
- Where
- 33 sites in Thailand
- Volunteers
- 4,000 people
- Sponsor
- Mahidol University
Influenza
Safety of the Intramuscular Route of the Anti-Flu Vaccine in Patients Receiving Oral Anticoagulation Therapy
Until now, the best administration route of the anti-flu vaccine for patients receiving long term oral anticoagulation therapy has been the subcutaneous one; the intramuscular route has not been recommended because it may…
- Trial name
- NCT00137579
- Testing
- Influenza vaccine intramuscular administration route
- Where
- 4 sites in Spain
- Volunteers
- 216 people
- Sponsor
- Catalan Institute of Health
Atrial Fibrillation, Thromboembolism, Venous
DOCE Study Interaction Between Direct Oral Anticoagulants and Drug-metabolizing Enzyme Inducers
Aim of the study is to investigate whether the influence of drugs inducing of CYP 3A4 isoenzyme of CYP450 and P-gp transporter significantly affect plasma levels of DOACs in patients with NVAF and venous thromboembolism
- Trial name
- NCT05750680
- Testing
- DOACs
- Where
- Italy
- Volunteers
- 23 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Chronic Subdural Hematoma, Atrial Fibrillation (AF)
Restarting Early Versus Later Anticoagulation for Chronic Subdural Hematoma With Atrial Fibrillation
The goal of this randomized clinical trial is to assess the benefit of early resumption versus late resumption of oral anticoagulation medication in adults with atrial fibrillation undergoing surgery for chronic subdural…
- Trial name
- RELACS (NCT06696079)
- Testing
- Early Resumption of Oral Anticoagulation Therapy, Late Resumption of Oral Anticoagulation Therapy
- Where
- 6 sites in Finland, Sweden
- Volunteers
- 332 people
- Sponsor
- Rahul Raj
Acute Ischemic Stroke
Efficacy and Safety of Tenecteplase Among acutE Ischemic Stroke Patients With Recent Ingestion of Direct Oral Anticoagulant
The study will randomize patients with acute ischemic stroke and Direct Oral AntiCoagulants (DOAC) ingestion within 48 hours from enrollment (but otherwise eligible for thrombolysis) to administration of intravenous tenecteplase…
- Trial name
- ESTER-DOAC (NCT07621796)
- Testing
- Intravenous tenecteplase (TNK)
- Where
- United States
- Volunteers
- 660 people
- Sponsor
- Hackensack Meridian Health
Epistaxis
Epistaxis in Patients Receiving Oral Anticoagulants and Antiplatelet: Prevalence Risk Factors at a Tertiary Care Hospital in Nepal
This study aims to determine the prevalence of epistaxis and identify the associated risk factors among patients receiving oral anticoagulants and antiplatelet at a tertiary care hospital in Nepal.
- Trial name
- Epistaxis (NCT06906861)
- Where
- Nepal
- Volunteers
- 284 people
- Sponsor
- Institute of medicine, Maharagjung medical campus
Atrial Fibrillation, Anticoagulant-induced Bleeding
Baseline Concentration of Direct Oral Anticoagulant and Incidence of Adverse Event Measure And See (MAS)
The MAS Study is an observational, multicentre, prospective cohort study in Non valvular Atrial fibrillation (NVAF) patients treated with one of the direct oral anticoagulants (DOACs) available in Italy for NVAF patients.
- Trial name
- MAS (NCT03803579)
- Where
- Italy
- Volunteers
- 2,000 people
- Sponsor
- Arianna Anticoagulazione Foundation
Venous Thromboembolism, Atrial Fibrillation
Observatory of Invasive Procedures and Bleeding in Patients Treated With New Oral Anticoagulants
The arrival on the market of direct oral factor Xa and factor IIa inhibitors (dabigatran (Pradaxa®), rivaroxaban (Xarelto®), apixaban (Eliquis®) and others soon to come) raises novel questions among clinicians confronted with the…
- Trial name
- GIHP-NACO (NCT02185027)
- Testing
- complications and compliance with GIHP recommendations
- Where
- 41 sites in Belgium, France
- Volunteers
- 1,166 people
- Sponsor
- University Hospital, Grenoble
Anticoagulant Therapy
In Vitro Diagnostic Test for DOAC in Urine
This trial is conducted to assess the performance and handling of the in vitro diagnostic (IVD) device for oral direct factor Xa and thrombin inhibitors from urine samples of patients on treatment with direct oral anticoagulants…
- Trial name
- PADOASU (NCT03182829)
- Testing
- DOAC Dipstick
- Where
- 18 sites in Germany
- Volunteers
- 880 people
- Sponsor
- Doasense GmbH
Atrial Fibrillation
The Association Between Non-vitamin K Antagonist Oral Anticoagulant Concentration and Clinical Outcomes.
Introduction: Non-vitamin K antagonist oral anticoagulants (NOAC) is the first line therapy to prevent ischemic stroke or systemic thromboembolism among atrial fibrillation (AF) patients.
- Trial name
- NCT05333666
- Testing
- Data collection
- Where
- 2 sites in Taiwan
- Volunteers
- 1,500 people
- Sponsor
- National Taiwan University Hospital
Deep Venous Thrombosis
Low Molecular Weight Heparin vs Direct Oral Anticoagulant After Bariatric Surgery
Extended Venous Thromboemboism Prophylaxis After Bariatric Surgeries: A Comparison Of Low Molecular Weight Heparin With Direct Oral Anticoagulant
- Trial name
- NCT06913595
- Testing
- Direct Oral Anticoagulant., Low Molecular Weight Heparine
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Cairo University